Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesare Gridelli

Showing results (111-120 of 357) with videos related to

Pageof 36
Sort By:
Expert Review of Respiratory Medicine|March 29, 2019
First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: state of the art and future developmentDanilo Rocco, Luigi Della Gravara, Ciro Battiloro, et al.
Expert Opinion on Pharmacotherapy|August 17, 2018
What pharmacotherapeutics should one use for early stage non-small cell lung cancer?Ciro Battiloro, Luigi Della Gravara, Danilo Rocco, et al.
Tumori|August 19, 2008
[The dilemma of first-line chemotherapy in advanced non-small-cell lung cancer: are third-generation drugs all the same?]Francesco Grossi, Filippo de Marinis, Luciano Frontini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Modulation of epidermal growth factor receptor-positive circulating tumor cells by chemotherapy in non-small-cell lung cancer patientsNicola Normanno, Antonella De Luca, Monica R Maiello, et al.
Journal of Thoracic Disease|March 31, 2018
J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?Cesare Gridelli, Francesca Casaluce, Assunta Sgambato, et al.
Translational Lung Cancer Research|May 18, 2016
Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that's the questionCesare Gridelli, Francesca Casaluce, Assunta Sgambato, et al.
Expert Opinion on Emerging Drugs|March 2, 2013
Emerging mitotic inhibitors for non-small cell carcinomaFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Annals of Translational Medicine|July 8, 2016
The role of pembrolizumab in the treatment of advanced non-small cell lung cancerGiuseppe Santabarbara, Paolo Maione, Antonio Rossi, et al.
Expert Opinion on Biological Therapy|March 8, 2016
Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancerTania Losanno, Antonio Rossi, Paolo Maione, et al.
Translational Lung Cancer Research|February 4, 2020
The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies eraAlessia Spagnuolo, Matteo Muto, Fabio Monaco, et al.
Pageof 36

Showing results (111-120 of 357) with videos related to

Sort By:
Pageof 36
Expert Review of Respiratory Medicine|March 29, 2019
First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: state of the art and future developmentDanilo Rocco, Luigi Della Gravara, Ciro Battiloro, et al.
Expert Opinion on Pharmacotherapy|August 17, 2018
What pharmacotherapeutics should one use for early stage non-small cell lung cancer?Ciro Battiloro, Luigi Della Gravara, Danilo Rocco, et al.
Tumori|August 19, 2008
[The dilemma of first-line chemotherapy in advanced non-small-cell lung cancer: are third-generation drugs all the same?]Francesco Grossi, Filippo de Marinis, Luciano Frontini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Modulation of epidermal growth factor receptor-positive circulating tumor cells by chemotherapy in non-small-cell lung cancer patientsNicola Normanno, Antonella De Luca, Monica R Maiello, et al.
Journal of Thoracic Disease|March 31, 2018
J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?Cesare Gridelli, Francesca Casaluce, Assunta Sgambato, et al.
Translational Lung Cancer Research|May 18, 2016
Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that's the questionCesare Gridelli, Francesca Casaluce, Assunta Sgambato, et al.
Expert Opinion on Emerging Drugs|March 2, 2013
Emerging mitotic inhibitors for non-small cell carcinomaFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Annals of Translational Medicine|July 8, 2016
The role of pembrolizumab in the treatment of advanced non-small cell lung cancerGiuseppe Santabarbara, Paolo Maione, Antonio Rossi, et al.
Expert Opinion on Biological Therapy|March 8, 2016
Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancerTania Losanno, Antonio Rossi, Paolo Maione, et al.
Translational Lung Cancer Research|February 4, 2020
The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies eraAlessia Spagnuolo, Matteo Muto, Fabio Monaco, et al.
Pageof 36